Polyinosinic:polycytidylic acid - PrEP Biopharm

Drug Profile

Polyinosinic:polycytidylic acid - PrEP Biopharm

Alternative Names: JNJ 43260295 AAM; Poly I: Poly C; Poly IC; Polyinosinic-polycytidylic acid sodium salt; PrEP 001; Product Number WO 643

Latest Information Update: 16 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Janssen Sciences Ireland UC
  • Developer hVIVO; Janssen Research & Development; Janssen Sciences Ireland UC; PrEP Biopharm
  • Class Adjuvants; Antineoplastics; Antivirals; Biopolymers; Oligonucleotides
  • Mechanism of Action 2',5' oligoadenylate synthetase modulators; DDX58 protein modulators; IFIH1 protein modulators; Immunomodulators; Proto oncogene protein c rel modulators; Toll-like receptor 3 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Influenza virus infections; Rhinovirus infections

Most Recent Events

  • 24 May 2017 Prep Biopharm completes a phase I trial in Healthy volunteers in United Kingdom (NCT03198676)
  • 08 May 2017 Prep Biopharm initiates enrolment in a phase I trial in Healthy volunteers in United Kingdom (NCT03198676)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top